Definitive Healthcare Corp. (DH) AI Stock Analysis

Definitive Healthcare Corp., founded in 2011 and based in Framingham, Massachusetts, delivers commercial intelligence solutions across the United States. The company provides data and insights on healthcare providers and their operational activities to clients in biopharmaceuticals, medical devices, healthcare IT, staffing, commercial real estate, and financial institutions. Its primary product is an intelligence platform comprising 16 specialized modules. These modules assist users with sales, marketing, clinical research, product development, strategy formulation, talent acquisition, and physician network management to support go-to-market execution and improve operational efficiencies.

Revenue rose from $166.2M in FY2021 to a peak of $252.2M in FY2024 before declining 4.2% to $241.5M in FY2025. Gross margin stood at 75.9% in FY2025, compared to 81.1% in FY2023 and 75.5% in FY2021. Operating margin was -8.5% in FY2025, an improvement from -281.8% in FY2024. Net income has remained negative over the five-year stretch, ending FY2025 at -$138.9M. For the trailing twelve months, revenue was $232.7M with an operating margin of -8.6% and a net profit margin of -72.3%. In the latest quarter ended June 30, 2026, quarterly revenue fell 9.1% year-over-year.

As of June 30, 2026, the company held $183.6M in cash and short-term investments against $167.1M in total debt, resulting in net cash of $16.5M. Total assets stood at $496.8M and shareholders' equity was $144.7M, yielding a debt-to-equity ratio of 1.15 and a current ratio of 1.86. In FY2025, capital expenditures were $16.7M, while cash used for share buybacks reached $49.5M alongside $3.1M in dividends paid.

At $1.00, Definitive Healthcare trades at an enterprise value of $91.3M and a market capitalization of $106.7M. The stock trades at a forward P/E of 5.3x, compared to 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales ratio is 0.5x versus the peer median of 4.1x, while its EV/EBITDA is 46.7x against the peer median of 12.0x. Over the past 1 year, the stock fell 65.9%, trailing the S&P 500 (SPY) gain of 16.8%. Over 5 years, the stock is down 97.6% compared to an 83.0% gain for the index.

Wall Street coverage includes 1 Strong Buy, 5 Holds, and 1 Sell recommendation among 7 analysts. The mean price target is $1.90, representing a 90.0% premium over the last close of $1.00. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $221.3M and EPS of $0.19, reflecting an EPS decrease of 18.9%. Definitive Healthcare beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Definitive Healthcare Corp. (DH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DH income statement, DH balance sheet, DH key metrics, DH analyst forecast, DH chart. See the DH stock overview for the latest quote and news.